How does ACTI BTA's pb Ratio compare to its peers?

ACTI BTA is expensive based on its Price-To-Book Ratio (113.5x) compared to the peer average (6.1x).

How does ACTI BTA's pb Ratio compare vs other companies in the SE Biotechs Industry?

ACTI BTA is expensive based on its Price-To-Book Ratio (113.5x) compared to the Swedish Biotechs industry average (2.6x).

What is ACTI BTA's pb Ratio compared to its Fair pb Ratio? This is the expected pb Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ACTI BTA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of ACTI BTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ACTI BTA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Active Biotech (OM:ACTI BTA) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ACTI BTA Stock Overview

A biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. More details

ACTI BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 134.07% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (SEK0)

Has less than 1 year of cash runway

Shares are highly illiquid

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Active Biotech AB (publ) Competitors

Lipum

OM:LIPUM

SEK 352.1m

Abliva

OM:ABLI

SEK 702.8m

Isofol Medical

OM:ISOFOL

SEK 282.7m

Hamlet BioPharma

NGM:HAMLET B

SEK 604.1m

Price History & Performance

Summary of share price highs, lows and changes for Active Biotech
Historical stock prices
Current Share Price	SEK 0.12
52 Week High	SEK 0.29
52 Week Low	SEK 0.11
Beta	0.46
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-3.41%

Recent updates

Shareholder Returns

	ACTI BTA	SE Biotechs	SE Market
7D	-18.6%	-3.1%	2.1%
1Y	n/a	10.7%	13.5%

Return vs Industry: Insufficient data to determine how ACTI BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how ACTI BTA performed against the Swedish Market.

Price Volatility

Is ACTI BTA's price volatile compared to industry and market?
ACTI BTA volatility
ACTI BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.6%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	12.0%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: ACTI BTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine ACTI BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1983	6	Helen Tuvesson	www.activebiotech.com

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.

Active Biotech AB (publ) Fundamentals Summary

How do Active Biotech's earnings and revenue compare to its market cap?
ACTI BTA fundamental statistics
Market cap	SEK 158.94m
Earnings (TTM)	-SEK 41.60m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.8x

P/E Ratio

Is ACTI BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACTI BTA income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 41.60m
Earnings	-SEK 41.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)	-0.034
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ACTI BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/06 00:59
End of Day Share Price	2024/12/04 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Active Biotech AB (publ) is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Morten Larsen	ABG Sundal Collier
Stefan Waldenlind	Carnegie Investment Bank AB
Thomas Bowers	Danske Bank